12:00 AM
 | 
Oct 25, 1999
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Zevalin ibritumomab tiuxetan (IDEC-Y2B8): Completed Phase III studies enrollment

Idec Pharmaceuticals Corp. (IDPH), San Diego, Calif.
Product: Zevalin ibritumomab tiuxetan ( IDEC-Y2B8)
Business: Cancer...

Read the full 69 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >